Funds and ETFs Incyte Corporation

INCY

US45337C1027

Name	Weight	AuM	1st Jan change	Investor Rating
LYXOR MSCI USA ESG LEADERS EXTRA (DR) UCITS ETF - ACC - USD	0.06%	330 M€	-.--%
ANFIELD U.S. EQUITY SECTOR ROTATION ETF - USD	0.06%	85 M€	+14.41%	-
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.05%	0 M€	0.00%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A - EUR HEDGED	0.05%	8 M€	+7.41%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A (EUR) - EUR	0.05%	744 M€	+9.42%
REVERE SECTOR OPPORTUNITY ETF - USD	0.05%	6 M€	+17.98%	-
AGILITY SHARES MANAGED RISK ETF - USD	0.05%	121 M€	+8.66%	-
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.04%	276 M€	+11.40%	-
CSIF (IE) MSCI USA BLUE UCITS ETF B ACC - USD	0.04%	2,517 M€	+13.43%	-
NEXT FUNDS S&P 500 (UNHEDGED) ETF - JPY	0.04%	57 M€	+22.51%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.03%	283 M€	+21.38%
HSBC MSCI USA UCITS ETF - USD	0.03%	34 M€	+12.87%	-
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - DAILY HEDGED TO EUR - ACC - HEDGED EUR	0.03%	273 M€	-.--%
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.03%	655 M€	-.--%	-
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - DIST - USD	0.03%	1,174 M€	+23.54%
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.02%	205 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.02%	391 M€	+9.24%	-
NIGHTSHARES 500 1X/1.5X ETF - USD	0.02%	14 M€	+16.19%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR ETF - USD	0.02%	571 M€	+8.81%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.02%	206 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	34 M€	+9.50%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.02%	284 M€	-.--%
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.02%	607 M€	+0.05%	-
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.02%	1,166 M€	+0.26%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - USD	0.02%	23 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - EUR	0.02%	786 M€	-.--%

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

12/06/2024 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.19 USD

Average target price

73.35 USD

Spread / Average Target

+28.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-8.58%	12.84B
CSL LIMITED	-3.15%	89.69B
SAMSUNG BIOLOGICS CO.,LTD.	+2.50%	41.34B
BIOGEN INC.	-12.01%	33.72B
UCB	+62.74%	26.11B
BIOMARIN PHARMACEUTICAL INC.	-19.79%	14.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.34%	11.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.92%	11.52B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.92B
INNOVENT BIOLOGICS, INC.	-10.64%	8.38B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 21/05/2024 BST			5-day change	1st Jan Change
57.4 ^USD	+0.37%		+0.61%	-8.58%

07:58pm	Incyte Acquires 2 Office Buildings in Delaware	MT
05-15	Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM